Paradigm shift in the pathophysiology of postmenopausal and thyrotoxic osteoporosis

Mount Sinai Journal of Medicine

Volumn 76, Issue 5, 2009, Pages 474-483

  Zaidi, Mone ^a   Iqbal, Jameel ^a   Blair, Harry C ^b   Zallone, Alberta ^c   Davies, Terry ^a   Sun, Li ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Bone loss; Follicle stimulating hormone; Osteoclast; Osteopenia; Postmenopausal osteoporosis; Thyroid stimulating hormone; Thyrotoxic osteoporosis

Indexed keywords

ESTROGEN; FOLLITROPIN; HYPOPHYSIS HORMONE; LEVOTHYROXINE; LIOTHYRONINE; PARATHYROID HORMONE; RECOMBINANT THYROTROPIN; SEX HORMONE; THYROID HORMONE; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE;

AGING; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE REMODELING; BONE TURNOVER; CELL DAMAGE; CLINICAL TRIAL; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ESTROGEN DEFICIENCY; FEEDBACK SYSTEM; FRAGILITY FRACTURE; GENETIC DISORDER; GENETIC POLYMORPHISM; GRAVES DISEASE; HOMEOSTASIS; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOGONADISM; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SINGLE DRUG DOSE; THYROID CANCER; THYROID DISEASE; THYROTOXICOSIS; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; THYROTOXICOSIS; THYROTROPIN; UNITED STATES;

EID: 70350721782     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20136     Document Type: Review

References (64)

1. Stepnick LS. The frequency of bone disease. In: McGowan JA, Raisz LG, Noonan AS, Elderkin AL, eds. Bone Health and Osteoporosis: A Report of the Surgeon General. Washington, DC: Office of the US Surgeon General; 2004; 68-87.
2. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999; 130: 750-758.
3. Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4: 319-326. (Pubitemid 24295429)
4. Baran DT. Thyroid hormone and bone mass: the clinician's dilemma. Thyroid 1994; 4: 143-144. (Pubitemid 24202344)
5. Albright F, Smith PH, Richardson AM. Post menopausal osteoporosis. JAMA 1941; 1167: 2465-2474.
6. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302. (Pubitemid 34651948)
7. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-jun repression. Proc Natl Acad Sci U S A 2000; 97: 7829-7834.
8. Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decreases osteoclast formation by downregulating receptor activator for NF-kappa B ligand induced JNK activation. J Biol Chem 2002; 276: 8836-8840. (Pubitemid 37385456)
9. Srivastava S, Weitzmann MN, Kimble RB, et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Invest 1998; 102: 1850-1859. (Pubitemid 28533832)
10. Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001; 98: 13960-13965. (Pubitemid 33116006)
11. Garcí a Palacios V, Robinson LJ, Borysenko CW, et al. Negative regulation of RANKL induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens. J Biol Chem 2005; 280: 13720-13727.
12. Armour KE, Armour KJ, Gallagher ME, et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001; 142: 760-766.
13. Jagger CJ, Chow JW, Chambers TJ. Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone. J Clin Invest 1996; 98: 2351-2357.
14. Randolph JF, Sowers M, Bondarenko IV, et al. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004; 89: 1555-1561. (Pubitemid 38507902)
15. Sowers MR, Jannausch M, McConnell D, et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab 2006; 91: 1261-1267.
16. Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004; 19: 1628-1633. (Pubitemid 41094325)
17. Akhter MP, Lappe JM, Davies KM, Recker RR. Transmenopausal changes in the trabecular bone structure. Bone 2007; 41: 111-116. (Pubitemid 46891901)
18. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell 2006; 125: 247-260.
19. Wu Y, Torchia J, Yao W, et al. Bone microenvironment specific roles of ITAM adapter signaling during bone remodeling induced by acute estrogen deficiency. PLoS One 2007; 2: e586.
20. Iqbal J, Sun L, Kumar TR, et al. Follicle stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 2006; 103: 14925-14930. (Pubitemid 44527830)
21. Gao J, Tiwari-Pandey R, Samadfam R, et al. Altered ovarian function affects skeletal homeostasis independent of the action of follicle stimulating hormone. Endocrinology 2007; 148: 2613-2621. (Pubitemid 46984812)
22. Miyaura C, Toda K, Inada M, et al. Sex- and age-related response to aromatase deficiency in bone. Biochem Biophys Res Commun 2001; 280: 1062-1068. (Pubitemid 32924448)
23. Sims NA, Dupont S, Krust A, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptor-beta in bone remodeling in females but not in males. Bone 2002; 30: 18-25. (Pubitemid 34044296)
24. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130: 811-823. (Pubitemid 47332572)
25. Dawson-Hughes B. Bone loss accompanying medical therapies. N Engl J Med 2001; 345: 989-992. (Pubitemid 34940817)
26. Sowers MR, Greendale GA, Bondarenko J, et al. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 2003; 14: 191-197.
27. Xu ZR, Wang AH, Wu XP, et al. Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women. Clin Chim Acta 2009; 400: 8-13.
28. Devleta B, Adem B, Seneda S. Hypergonadotropic amenorrhea and bone density: new approach to an old problem. J Bone Miner Res 2004; 22: 360-364. (Pubitemid 38980953)
29. Von Recklinghausen F. Die Fibrose Oder Deformierende Ostitis, die Osteomalazie und die Osteoplastische Carzinose in Ihren Gegenseitigen Beziehungen. Berlin, Germany: George Reimer; 1891.
30. Murphy E, Williams GR. The thyroid and the skeleton. Clin Endocrinol 2004; 61: 285-298.
31. Wenzel KW. Thyroid hormone and bone. Thyroid 1994; 4: 508-509.
32. Allain TJ, Chambers TJ, Flanagan AM, McGregor AM. Tri-iodothyronine stimulates rat osteoclastic bone resorption by an indirect effect. J Endocrinol 1992; 133: 327-331.
33. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994; 134: 169-176.
34. Kim CH, Kim HK, Shong YK, et al. Thyroid hormone stimulates basal and interleukin (IL) - 1-induced IL-6 production in human bone marrow stromal cells: a possible mediator of thyroid hormone-induced bone loss. J Endocrinol 1999; 160: 97-102.
35. Ishikawa Y, Genge BR, Wuthier RE, Wu LN. Thyroid hormone inhibits growth and stimulates terminal differentiation of epiphyseal growth plate chondrocytes. J Bone Miner Res 1998; 13: 1398-1411. (Pubitemid 28418906)
36. Bassett JH, Nordström K, Boyde A, et al. Thyroid status during skeletal development determines adult bone structure and mineralization. Mol Endocrinol 2007; 21: 1893-1904. (Pubitemid 47173799)
37. De Menis E, Da Rin G, Roiter I, et al. Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm Res 1992; 37: 217-220. (Pubitemid 23053663)
38. Kisakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003; 50: 657-661. (Pubitemid 38139947)
39. Földes J, Tarján G, Szathmari M, et al. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol 1993; 39: 521-527. (Pubitemid 23323948)
40. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999; 9: 539-543. (Pubitemid 29296115)
41. Kindblom JM, Gevers EF, Skrtic SM, et al. Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone 2005; 36: 607-616.
42. Göthe S, Wang Z, Ng L, et al. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev 1999; 13: 1329-1341. (Pubitemid 29250200)
43. Bauer DC, Ettinger B, Nevitt MC, et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134: 561-568. (Pubitemid 32245317)
44. Morris MS. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 2007; 40: 1128-1134.
45. Bassett JH, O'Shea PJ, Sriskantharajah S, et al. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 2007; 21: 1095-1107. (Pubitemid 46984761)
46. Bassett D, Williams G. The skeletal phenotypes of TRalpha and TRbeta mutant mice. J Mol Endocrinol 2008; 42: 269-282.
47. Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 151-162. (Pubitemid 37329579)
48. Novack D. TSH, the bone suppressing hormone. Cell 2003; 115: 129-130.
49. Zaidi M, Sun L, Davies TF, Abe E. Low TSH triggers bone loss: fact or fiction? Thyroid 2006; 16: 1075-1076. (Pubitemid 44864481)
50. Hase H, Ando T, Eldeiry L, et al. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci U S A 2006; 103: 12849-12854. (Pubitemid 44298650)
51. Sun L, Vukicevic S, Baliram R, et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 2008; 105: 4289-4294. (Pubitemid 351754373)
52. Mazziotti G, Sorvillo F, Piscopo M, et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 2005; 20: 480-486. (Pubitemid 40293497)
53. Sampath TK, Simic P, Sendak R, et al. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 2007; 22: 849-859. (Pubitemid 351339745)
54. Giusti M, Cecoli F, Ghiara C, et al. Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappa beta ligand in patients under evaluation for differentiated thyroid carcinoma. Hormones (Athens) 2007; 6: 304-313.
55. Martini G, Gennari L, De Paola V, et al. The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid 2008; 18: 455-460.
56. Zofkova I, Hill M. Biochemical markers of bone remodeling correlate negatively with circulating TSH in postmenopausal women. Endocr Regul 2008; 42: 121-127.
57. La Vignera S, Vicari E, Tumino S, et al. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history. Minerva Ginecol 2008; 60: 475-484.
58. Heemstra KA, van der Deure WM, Peeters RP, et al. Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma. Eur J Endocrinol 2008; 159: 69-76.
59. Mikosch P, Kerschan-Schindl K, Woloszczuk W, et al. High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy. Thyroid 2008; 18: 27-33. (Pubitemid 351170452)
60. Grimnes G, Emaus N, Joakimsen RM, et al. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study. Thyroid 2008; 18: 1147-1155.
61. Nagata M, Suzuki A, Sekiguchi S, et al. Subclinical hypothyroidism is related to lower heel QUS in postmenopausal women. Endocr J 2007; 54: 625-630. (Pubitemid 47414613)
62. Van der Deure WM, Uitterlinden AG, Hofman A, et al. Effects of serum TSH and FT4 levels and the TSHR Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf) 2008; 68: 175-181.
63. Albagha OME, Natarajan R, Reid DM, et al. The D272E polymorphism of the human thyroid stimulating hormone receptor is associated with bone mineral density and bone loss in women from the UK. J Bone Miner Res 2005; 20: S341.
64. Rannevik G, Jeppsson S, Johnell O, et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 2008; 61: 67-77.